Eschbach and colleagues4 later reported marked improvement in EPO responsiveness with the addition of IV iron in the treatment paradigm for anemia chronic kidney disease (CKD) even with iron parameters consistent with iron repletion. This evidence concerns the gene EPO and chronic kidney disease.